AlphaTON Capital Corp — Regulatory Filings 2024

May 1, 2024

424B3 1 f424b3_043024.htm 424B3

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-275229

PROSPECTUS SUPPLEMENT

(to Prospectus dated November 7, 2023)

Portage Biotech Inc.

9,631,580 Ordinary Shares underlying Warrants

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-275229), with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on April 30, 2024 (the “April 30, 2024 Form 6-K”). Accordingly, we have attached the April 30, 2024 Form 6-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our Ordinary Shares are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “PRTG”. On April 30, 2024, the closing sale price of our Ordinary Shares as reported on Nasdaq was $0.24.

___________________________

Investing in the securities offered in the Prospectus involves a high degree of risk. Before making any investment in these securities, you should consider carefully the risks and uncertainties in the section entitled “Risk Factors” beginning on page 9 of the Prospectus, and in the other documents that are incorporated by reference into the Prospectus.

Neither the Securities and Exchange Commission nor any state or non-U.S. regulatory body has approved or disapproved of the securities offered in the Prospectus or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

___________________________

The date of this prospectus supplement is April 30, 2024

Field: Page; Sequence: 1

Field: /Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2024

Commission File Number: 001-40086

Portage Biotech Inc.

(Translation of registrant’s name into English)

Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Field: Rule-Page

Field: /Rule-Page

INCORPORATION BY REFERENCE

This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Director Resignations

On April 25, 2024, Mark J. Simon notified Portage Biotech Inc. (the “Company”) of his decision to resign from the board of directors of the Company (the “Board”) and all committees thereof, effective immediately.

On April 26, 2024, Linda M. Kozick and Robert H. Glassman, M.D. notified the Company of their respective decisions to resign from the Board and all committees thereof, both effective immediately.

Director Appointments

On April 30, 2024, the Board appointed Jean-Christophe Renondin, M.D. and Justin Stebbing, M.D., Ph.D. as directors. Both Dr. Renondin and Dr. Stebbing have been appointed to the Nominating Committee of the Board and the Audit Committee of the Board.

Each of Dr. Renondin and Dr. Stebbing’s compensation will be consistent with the compensation provided to the Company’s non-employee directors, as described in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2023 filed with the Securities and Exchange Commission on July 31, 2023.

No arrangement or understanding exists between either Dr. Renondin or Dr. Stebbing and any other person pursuant to which Dr. Renondin and Dr. Stebbing were appointed as directors. There are no transactions in which either Dr. Renondin or Dr. Stebbing has an interest which would require disclosure under Item 404(a) of Regulation S-K.

The current composition of the committees of the Board is as follows:

· Audit Committee : Steven Mintz (Chair) , Jean-Christophe Renondin and Justin Stebbing

· Nominating Committee : Jean-Christophe Renondin (Chair), Gregory Bailey and Justin Stebbing

· Compensation Committee : James Mellon (Chair), Gregory Bailey and Steven Mintz

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 30, 2024

PORTAGE BIOTECH INC.

By:
Allan Shaw
Chief Financial Officer

Field: Rule-Page

Field: /Rule-Page